✨ Free AI Report
Septerna, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Septerna, Inc.
Company Research

Septerna, Inc.: Business Overview, Financials & Competitive Analysis

Septerna, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage GPCR biotech with validated platform, major pharma partnership, strong cash position, and near-term clinical readouts across multiple therapeutic areas. Septerna has strong financial runway with $561.6M in cash, equivalents, and marketable securities including a $195M Novo Nordisk upfront payment, with expected runway into at least 2029. Recent positive Phase.

What is Septerna, Inc.'s industry? Septerna, Inc. (septerna.com) operates in Biotechnology - Clinical Stage GPCR Drug Discovery. AskCyborg classifies Septerna, Inc. under Biotechnology - Clinical Stage GPCR Drug Discovery in its company registry.

Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. The company's proprietary Native Complex Platform® is designed to en...

7/ 10Strong

Cyborg Score thesis

Clinical-stage GPCR biotech with validated platform, major pharma partnership, strong cash position, and near-term clinical...

Read the full analyst-debate transcript →
Industry Biotechnology - Clinical Stage GPCR Drug Discovery
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Septerna, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Septerna, Inc.

AskCyborg analysts argue the bull and bear cases for Septerna, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Septerna, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Septerna, Inc. Overview

Pro stress-test →

Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. The company's proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas.

Strategic Profile

Pro stress-test →

The company has a global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Analyst sentiment remains bullish with eight buy ratings and no hold or sell ratings, with an average target price of $33.86 indicating potential upside of 11.81% from current levels.

Competitive Landscape

Pro stress-test →

Septerna focuses on developing GPCR oral small molecule products targeting endocrinology, immunology, inflammation, and metabolic disorders. The company competes in the clinical-stage biotech space against other GPCR-focused platforms and larger pharma companies developing therapies in metabolic and immunology indications. Its Novo Nordisk partnership validates its proprietary platform approach and provides significant capital advantage over most competitors.

Industry Context

Septerna, Inc. operates in Biotechnology - Clinical Stage GPCR Drug Discovery.

Key facts

Founded: 2019 · Headquarters: South San Francisco, California · Employees: 200-300 · Revenue: $15M-20M · Market cap: $1.32B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Septerna, Inc..

  • Positive Phase 1 data for SEP-631 (MRGPRX2 NAM) supports planned Phase 2b trial in chronic spontaneous urticaria with expansion into broader mast cell disease indications (March 2026)
  • SEP-479 selected as next-generation oral PTH1R agonist for hypoparathyroidism with Phase 1 trial planned in H1 2026
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Positive Phase 1 data for SEP-631 announced with Phase 2b CSU trial planned
  • February 2026CEO presentation at TD Cowen Healthcare Conference (March 3, 2026)
  • +2 moreTrack every material event for Septerna, Inc. as it happens. Explore monitoring →
Get alerted when Septerna, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GPCR Therapeutics PlatformClinical-stage GPCR drug discovery→Metabolic Disease SolutionsGLP-1 and obesity/metabolic disorder focus→Allergy/Immunology ProgramsMast cell and immunology indications→Thyroid Disease PlatformMetabolic and endocrine disease focus→

Compare Septerna, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Septerna, Inc. operates in Biotechnology - Clinical Stage GPCR Drug Discovery. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Clinical Stage GPCR Drug Discovery research →
NEW · MCP server

Ask your AI assistant about Septerna, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Septerna, Inc. and its top competitor on Cyborg Score”
“What did Septerna, Inc. do this quarter?”
“Is Septerna, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Septerna, Inc. do?+
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. The company's proprietary Native Complex Platform® is designed to en...
What is Septerna, Inc.'s Cyborg Score?+
Septerna, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Septerna, Inc.'s main competitors?+
Named competitors include GPCR Therapeutics Platform, Metabolic Disease Solutions, Allergy/Immunology Programs, Thyroid Disease Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Septerna, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Septerna, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Septerna, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.